OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomicsECCO'18 Vienna 2018
1
OP006: Apremilast for active Ulcerative Colitis: A phase 2, randomised, double-blind, placebo-controlled induction studyECCO'18 Vienna 2018
1
OP007: Detection of mucosal healing with a serum marker panel in adalimumab treated patients with Ulcerative ColitisECCO'18 Vienna 2018
1
OP009: A combination of clinical, serological and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study.ECCO'18 Vienna 2018
1
OP010: Shallow whole genome sequencing predicts the future cancer risk of low grade dysplastic lesions arising in Ulcerative ColitisECCO'18 Vienna 2018
1
OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's DiseaseECCO'18 Vienna 2018
OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndromeECCO'18 Vienna 2018
1
OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014ECCO'18 Vienna 2018
1
OP017: Transanal minimally-invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international databaseECCO'18 Vienna 2018
1
OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signalingECCO'18 Vienna 2018
1
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST studyECCO'18 Vienna 2018
1
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn’s Disease (CD)ECCO'18 Vienna 2018
1
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II studyECCO'18 Vienna 2018
1
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysisECCO'18 Vienna 2018
1
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score–matched analysisECCO'18 Vienna 2018
1